All In Biotech

Drug Trial Radar · NCT07797153

JSKN033 Versus Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Cancer

A Randomized, Controlled, Open-Label, Multi-center, Phase III Study of JSKN033 Versus Investigator's Choice of Chemotherapy in Patients With Recurrent or Metastatic Cervical Cancer Who Have Failed Platinum-Based Chemotherapy and PD-1/L1 Inhibitor Therapy

Last checked: Nov 19, 2026Latest source record: Sep 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 368 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

368

Planned (sponsor's estimate)

Start

Sep 2026

Primary completion

Dec 2028

Study completion Dec 2029

Sponsor

Sponsor type
Industry
First posted
Sep 1, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a randomized, open-label, controlled, phase III study to evaluate the efficacy and safety of JSKN033 versus investigator's choice of chemotherapy in patients with recurrent or metastatic cervical cancer who have failed platinum-based chemotherapy and PD-1/L1 inhibitor therapy.

Conditions

  • Recurrent or Metastatic Cervical Cancer

Interventions

  • JSKN033Drug

    JSKN033 should be administered subcutaneously

  • DocetaxelDrug

    Docetaxel

  • TopotecanDrug

    Topotecan

  • Gemcitabine (GEM)Drug

    Gemcitabine

  • PemetrexedDrug

    Pemetrexed

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free Survival (PFS) assessed by Blinded Independent Review Committee (BIRC) as per RECIST 1.1Time frame: Up to approximately 27 months
  2. Overall Survival (OS)Time frame: Up to approximately 27 months

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Affiliated Cancer Hospital of Fudan University

    Shanghai, China

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.